Gian Oddone
The DBTL cycle does not complete without the T. Without rich datasets from scale-down fermentations in the 10s to 100s of mL scale, strain improvements languish in the realm of theory. They may be the casualties of noise overwhelming signal, or no vacancy in the bioreactor. Dr. Gian Oddone, in his 16-year career developing industrial bioprocesses for converting sugar to enzymes, chemicals, biopesticides, nutrients and therapeutics, knows the strain-overloaded testing problem well. At Biolucid LLC, Dr. Oddone helps clients develop their research platforms, tools, and bioprocess technologies, applying his metabolic engineering expertise, scientific rigor, and flexible automation/programming solutions to light a path to commercialization. Dr. Oddone has previously held bioprocess leadership roles at Genomatica (now Geno), Marrone Bio Innovations (now Profarm), and Novozymes (now Novonesis).
Biolucid
Converging Platforms: High-Throughput and Analytical Solutions Driving Biotech Breakthroughs
-
Explore how cutting-edge microelectronics, spectroscopy, advanced liquid-handling systems, and powerful bioinformatics converge to accelerate innovation across biotech, pharmaceuticals, and synthetic biology. By leveraging integrated approaches—spanning machine learning tools, next-generation lab automation, and modular high-throughput platforms—industry leaders are redefining what’s possible from early R&D to commercial-scale production. Gain insights into the core technologies and collaborative models fueling these breakthroughs, and learn how this convergence is reshaping discovery pipelines, enhancing product development, and pushing the boundaries of what we can achieve in healthcare, bioactives, and beyond.
